Close Menu
Home » Illumina Receives FDA Approval for Companion Dx to Run on MiSeqDx

Illumina Receives FDA Approval for Companion Dx to Run on MiSeqDx

Jun 29, 2017
|
staff reporter

This article has been corrected to note that Illumina's test is the third NGS-based companion diagnostic to be approved by the FDA, not the second as previously reported.

NEW YORK (GenomeWeb) – Illumina has received US Food and Drug Administration approval for a companion diagnostic test, which it has been developing with Amgen, to run on its MiSeqDx system, the company said after the close of the market on Thursday.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Hahn Hearing

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

RNAi Drug for Acute Hepatic Porphyria

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Decade of DTC

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

Nature Studies Examine Native RNA Sequencing, Nanopore Sequencing Approach to Analyze STR Expansions

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.

Dec
02
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of   FLT3  and  CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Dec
04
Featured Webinar

Integrating Genetic Data in Clinical Workflows: How CCPM Established a Personalized Health Framework

Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).

Dec
11
Featured Webinar

Advances in Precision Oncology: Tertiary Analysis Software for Solid Tumor NGS

Sponsored by
Roche

This webinar will address how two molecular laboratories are implementing tertiary analysis software to improve their precision oncology workflows.

What's Popular?

In Molecular Diagnostics

  1. Despite FDA Clearance for NantHealth Test, Benefits of TMB Biomarker Unclear

    Premium

  2. Cancer Diagnostics Firm Lucence Raises $20M

  3. T2 Biosystems Gets CE Mark for Direct-From-Blood Antimicrobial Resistance Panel

  4. Qiagen Says It Is Fielding Acquisition Offers

  5. Exact Sciences Marker Panel Detects Early Liver Cancer With Triple Sensitivity of Current Biomarker

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.